65,437 trials
Diabetes Mellitus, Type 2
Primary: Change of HbA1c From Baseline at Week 12 — 2.14; 2.10; 1.95; 2.02 ln(percent) — p=<0.0001
Colorectal Cancer
Primary: Progression-free Survival — 9.1; 5.1 Months — p=<0.001
Tuberculosis · AIDS-related Complex
Primary: Sputum Conversion — 36; 60; 36 percentage of participants
Recurrent Uterine Sarcoma · Stage III Uterine Sarcoma · Stage IV Uterine Sarcoma
Primary: Objective Overall Response Rate — 2; 0 participants
Prediabetes · Overweight
Primary: Effect of "FRESH" Program on Weight Loss — -0.5; -0.2 kg — p=0.72
Ventral Hernias
Primary: Visual Analog Scale of Pain Activity — 50; 70 units on a scale
HIV Infections · Fatigue
Primary: Fatigue Severity Scale (FSS) — 52; 52; 34; 43 units on a scale — p=< 0.001
Vegetative State · Minimally Conscious State · Disorders of Consciousness
Primary: Change in CRS-R Total Scores — 12.17; 10.60 units on a scale
Obsessive-compulsive Disorder
Primary: OCD Severity — -2.7 units on a scale
Pregnancy · Polycystic Ovary Syndrome
Primary: Live Birth — 72; 103 Participants — p=0.007
Acute Lymphocytic Leukemia
Primary: Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years — 64.9 percentage of participants
Cocaine Abuse and Dependence
Primary: Cocaine Safety in Subjects Receiving Donepezil — 0; 2 Participants with an Adverse Event
Breast Cancer
Primary: Confirmed Response Rate (Complete and Partial) — 2 participants
Smoking Cessation
Primary: Continuous Abstinence Rate (CAR) From Week 9 Through Week 12 — 45.0; 11.8 Percentage of participants — p=<0.0001
Multiple Myeloma
Primary: The Proportion of Patients Alive and Without Progressive Disease (PD) for ≥6 Months — 75 percentage of treated patients